W
WAVEMAN · COMPANY
LGND · Ligand Pharmaceuticals Inc
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

LGND

LIGAND PHARMACEUTICALS INC
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000886163
CONGRESS · 1FORM 144 · 4☆ WATCH
INSIDER NET · 180D
-$23.8M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
1
FUNDS ADDED · QTR
248
13F, latest reported quarter
REVENUE GROWTH
+60.4%
XBRL, annual
NET MARGIN
46.4%
CONVERSIONS · 180D
19
codes C/M, not in net · $4.2M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$23.8M over 180 days
-$18.9M over 90 days
below 89% of Pharma & Biotech
CONGRESS
1 member bought in the last year
the lowest in Pharma & Biotech
FUNDS
248 funds added or opened last quarter
more than 91% of Pharma & Biotech
REVENUE
+60.4% year over year
more than 81% of Pharma & Biotech
MARGIN
46.4% net margin
more than 95% of Pharma & Biotech
BUYBACKS
$60.0M repurchased, FY to 2026-06-30
more than 59% of Pharma & Biotech
SHORT
10.9% of shares outstanding short · 7.4 days to cover · settled 2026-07-31
more than 80% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$23.8M across 7 people in 180 days.
248 funds added or opened positions in the latest 13F quarter, of 417 holders.
1 member of Congress reported buying it this year.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +77.0%
+77.0%12M
+0%+32%+65%+97%2025-092025-102025-122026-032026-052026-072026-09 2026-08-12 · Espinoza Octavio sold $9.2M2026-08-12 · Haas Jason sold $2.1M2026-06-11 · Aryeh Jason sold $1.1M2026-06-12 · Haas Jason sold $886.3K2026-06-10 · LAMATTINA JOHN L sold $856.8K2025-09-23 · Aryeh Jason sold $791.2K2026-06-12 · Haas Jason sold $765.0K2025-09-23 · Aryeh Jason sold $752.9K2025-11-07 · Gray Nancy Ryan sold $730.6K2026-03-04 · Espinoza Octavio sold $712.6K2026-03-11 · Espinoza Octavio sold $687.8K2025-11-07 · Gray Nancy Ryan sold $619.4K2026-06-16 · Sabba Stephen L sold $544.8K2026-03-04 · Espinoza Octavio sold $510.8K2025-11-07 · LAMATTINA JOHN L sold $440.7K2026-03-06 · LAMATTINA JOHN L sold $433.8K2025-11-07 · LAMATTINA JOHN L sold $417.9K2026-03-03 · Sabba Stephen L sold $409.9K2026-05-13 · KOZARICH JOHN W sold $352.0K2026-08-03 · Reardon Andrew sold $349.4K2026-07-01 · Reardon Andrew sold $348.8K2025-12-12 · Espinoza Octavio sold $339.7K2026-07-01 · Reardon Andrew sold $337.6K2026-05-01 · Reardon Andrew sold $330.7K2026-03-04 · Espinoza Octavio sold $328.5K2026-06-01 · Reardon Andrew sold $323.6K2026-03-04 · Reardon Andrew sold $300.9K2026-03-04 · Espinoza Octavio sold $299.8K2026-08-03 · Reardon Andrew sold $296.0K2026-08-03 · Reardon Andrew sold $289.1K2026-07-01 · Reardon Andrew sold $284.2K2026-06-01 · Reardon Andrew sold $279.0K2026-04-01 · Reardon Andrew sold $260.0K2026-04-01 · Reardon Andrew sold $248.8K2026-03-04 · Reardon Andrew sold $238.5K2026-07-01 · Reardon Andrew sold $219.4K2026-05-01 · Reardon Andrew sold $213.2K2026-03-23 · Sabba Stephen L sold $207.9K2026-04-01 · Reardon Andrew sold $195.7K2026-03-04 · Espinoza Octavio sold $191.6K2026-07-01 · Reardon Andrew sold $190.3K2026-05-01 · Reardon Andrew sold $187.2K2026-09-03 · ANDREW REARDON filed to sell $4.3M2026-08-12 · OCTAVIO ESPINOZA filed to sell $9.1M2026-08-12 · Jason Haas filed to sell $2.1M2026-07-01 · ANDREW REARDON filed to sell $3.2M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $23.8M sold by insiders over 180 days, 248 funds added last quarter, 1 Congress member(s) bought in 12 months, $18.7M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, LIGAND PHARMACEUTICALS INC insiders sold a net $23.8M of stock across 187 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Espinoza Octavio
Chief Financial Officer
SELL
2026-08-12
31,641.0
$9.2M
Haas Jason
Director
SELL
2026-08-12
7,138.0
$2.1M
Reardon Andrew
CLO & Secretary
SELL
2026-08-03
105.0
$29.8K
Reardon Andrew
CLO & Secretary
SELL
2026-08-03
33.0
$9.4K
Reardon Andrew
CLO & Secretary
SELL
2026-08-03
157.0
$44.9K
187 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 182 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
3,100,996.0 sh
$980.2M
Invesco Ltd.
1,201,644.0 sh
$379.8M
VANGUARD PORTFOLIO MANAGEMENT LLC
1,138,316.0 sh
$359.8M
Jupiter Topco LLC
1,040,578.0 sh
$328.9M
VANGUARD CAPITAL MANAGEMENT LLC
870,950.0 sh
$275.3M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
ANDREW REARDON
FILED 2026-09-03
$4.3M
OCTAVIO ESPINOZA
FILED 2026-08-12
$9.1M
Jason Haas
FILED 2026-08-12
$2.1M
ANDREW REARDON
FILED 2026-07-01
$3.2M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
DWS Small Cap Core Fund
$51.9M POSITION · AS OF 2026-03-31
4.9%
Ranger Micro Cap Fund
$520.9K POSITION · AS OF 2026-04-30
4.5%
Private Capital Management Value Fund
$2.9M POSITION · AS OF 2026-04-30
4.3%
Impax Small Cap Fund
$30.4M POSITION · AS OF 2026-03-31
4.1%
Transamerica Small Cap Growth
$3.0M POSITION · AS OF 2026-04-30
3.8%
Ranger Small Cap Fund
$820.3K POSITION · AS OF 2026-04-30
3.8%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$268.1M$167.1M$131.3M$196.2M
OPERATING INCOME$41.0M$-22.6M$11.9M$3.0M
NET INCOME$124.5M$-4.0M$52.2M$-33.4M
EPS (DILUTED)6.13-0.222.94-1.98
OPERATING CASH FLOW$49.4M$97.0M$49.6M$137.8M
CASH$174.9M$72.3M$23.0M$45.0M
BUYBACKS$15.0M$0$0$0
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →